Neoadjuvant FEC 100 for Operable Breast Cancer: Eight-Year Experience at Centre Jean Perrin-Reference-Cited by-同舟云学术

Neoadjuvant FEC 100 for Operable Breast Cancer: Eight-Year Experience at Centre Jean Perrin

Published:2004-10 Issue:4 Volume:5 Page:303-307
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Mouret-Reynier Marie-Ange,Abrial Catherine J.,Ferrière Jean-Pierre,Amat Sophie,Curé Hervé D.,Kwiatkowski Fabrice G.,Feillel Viviane A.,Lebouëdec Guillaume,Penault-Llorca Frédérique M.,Chollet Philippe J.M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference17 articles.

1. Indications for neoadjuvant chemotherapy for breast cancer;Bear;Semin Oncol,1998

2. Recently initiated studies: neoadjuvant treatments in the next century;Gradishar;Semin Oncol,1999

3. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre;Mauriac;Ann Oncol,1991

4. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer;Fisher;J Clin Oncol,1998

5. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute;Bonadonna;J Clin Oncol,1998

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epirubicina neoadyuvante con o sin docetaxel secuencial en el tratamiento del cáncer de mama avanzado: evaluación de la respuesta patológica completa y tolerabilidad de la quimioterapia;Cirugía y Cirujanos;2018-11-21

2. A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer;BMC Cancer;2016-08-05

3. Impacto pronóstico de la respuesta patológica completa y del estado ganglionar en pacientes con cáncer de mama avanzado tratadas con dosis alta de epirrubicina neoadyuvante;Gaceta Mexicana de Oncología;2016-05

4. Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute;Clinical Breast Cancer;2015-08

5. Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer;Breast Cancer Research and Treatment;2015-07-09